Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer
10:35am, Friday, 25'th Mar 2022 Zacks Investment Research
Novartis, Merck and Pfizer have been included in this Analyst Blog.
3 Brilliant Stocks to Buy in an Uncertain Market
09:56am, Friday, 25'th Mar 2022 The Motley Fool
Their underlying businesses are strong.
Pfizer's (PFE) Etrasimod Meets Ulcerative Colitis Study Goals
05:41pm, Thursday, 24'th Mar 2022 Zacks Investment Research
Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.
Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children
02:36pm, Thursday, 24'th Mar 2022 Zacks Investment Research
Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.
Pharma Stock Roundup: NVS, MRK Get FDA Nod, PFE Ulcerative Colitis Study Succeeds
02:14pm, Thursday, 24'th Mar 2022 Zacks Investment Research
FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto
Novartis AG (NYSE: NVS) said the U.S.
Moderna seeks regulatory nod for COVID vaccine in very young children, and WHO reports second straight week with cases rising globally
09:58am, Thursday, 24'th Mar 2022 MarketWatch
Moderna Inc. will seek an emergency use authorization from regulators in the U.S., Europe and elsewhere for its COVID-19 vaccine in babies, toddlers and preschoolers, after a late-stage trial found i
Is It Time to Buy COVID-19 Vaccine Stocks Again?
09:56am, Thursday, 24'th Mar 2022 The Motley Fool
The picture is improving for vaccine stocks. But there's still a lot of uncertainty.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
09:45pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
In the latest trading session, Pfizer (PFE) closed at $52.19, marking a -1.6% move from the previous day.
Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India
05:52pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.
Moderna's stock, down 60% since the summer's delta wave, is rising again as COVID-19 cases increase
12:16pm, Wednesday, 23'rd Mar 2022 MarketWatch
Moderna's stock has tumbled 63% from last summer's record high, but the recent resurgence of COVID-19 cases in Europe and Asia is already rallying shares.
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
11:38am, Wednesday, 23'rd Mar 2022 Zacks Investment Research
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
European countries lifted COVID restrictions 'too brutally,' says WHO regional head, allowing BA.2 variant to spread
10:36am, Wednesday, 23'rd Mar 2022 MarketWatch
European countries, including the UK, German and France, lifted their COVID-19 restrictions 'too brutally' and are now struggling with rising cases again as the highly transmissible BA.2 variant sprea
Is the FDA Slow-Walking Authorization of Novavax's COVID Vaccine?
09:56am, Wednesday, 23'rd Mar 2022 The Motley Fool
The FDA certainly doesn't seem to be in a hurry to grant Emergency Use Authorization to NVX-CoV2373.
Pfizer (PFE) Recalls Hypertension Drug Due to Impurities
02:21pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.
